Generated June 22, 2026 at 8:33 PM ET
· Covers June 22 trading day
· 10 of 262 ready 8-Ks selected
· AI-assisted overview
The day featured several high-materiality filings. Spero Therapeutics received FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. CRH announced a $8.5B acquisition of Arcosa, while Digital Realty made multiple strategic acquisitions including a 1,440-acre site for a 2GW campus and a stake increase in Teraco. AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9B. On the negative side, Verses AI discontinued AI operations after executive resignations over unpaid wages, and Primoris slashed its FY2026 guidance amid continued cost overruns in its Renewables segment, with its COO departing.
other material
negative
materiality 1.00
June 22, 2026, 2:58 PM ET
Verses AI discontinues AI operations, pursues strategic alternatives; President/COO, CTO resign over unpaid wages
- Discontinues AI R&D and related expenditures to preserve capital; no assurance of continued operations.
- President/COO James Hendrickson and CTO Hari Thiruvengada resign over non-payment of earned wages and compensation disagreements.
- CSO Karl Friston also resigns; licensing agreement with Prodigii AI, LLC terminated.
SPRO
Spero Therapeutics, Inc.
regulatory
positive
materiality 0.90
June 22, 2026, 4:05 PM ET
FDA approves Spero Therapeutics' Utebzi, first oral carbapenem for cUTIs
- Utebzi (tebipenem pivoxil) approved June 17, 2026 for complicated UTIs in adults with limited oral alternatives.
- PIVOT-PO trial showed 58.5% overall success vs 60.2% for IV imipenem-cilastatin (adjusted diff -1.3%).
- Most common AEs were diarrhea and headache; all mild/moderate and non-serious.
M&A
positive
materiality 0.90
June 22, 2026, 7:03 AM ET
CRH acquires Arcosa for $150/share (~$8.5B enterprise value); 25% premium
- Total enterprise value ~$8.5B; 11.5x 2026E Adj. EBITDA including $175M annual cost synergies by year 3.
- Arcosa operates 109 quarries (35M tons aggregates) and is top-3 in energy transmission infrastructure.
- Deal expected to be accretive to earnings, margin and cash flow within 12 months post-close.
—
DIGITAL REALTY TRUST, L.P.
M&A
positive
materiality 0.85
June 22, 2026, 9:17 AM ET
Digital Realty buys 1,440-acre site for 2GW campus, ups Teraco to 77%, acquires Columbia Capital for ~$485M
- Acquired 1,440 acres at Astra Enterprise Park near Kansas City for ~$475M; 600MW utility power by early 2028, 2GW at full delivery.
- Increasing Teraco ownership from ~61% to 77% by buying 16% stake for ~$650M, primarily via 3.4M shares of common stock.
- Acquiring Columbia Capital for ~$485M (including $45M cash, 2.3M shares at close) plus up to ~$275M earn-out; expected close 2H 2026.
APGE
Apogee Therapeutics, Inc.
M&A
positive
materiality 0.85
June 22, 2026, 7:45 AM ET
AbbVie to acquire Apogee Therapeutics for $135.11/share, ~$10.9B equity value
- AbbVie to acquire all outstanding shares of Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
- Acquisition expected to close in Q3 2026, subject to Apogee shareholder approval and regulatory clearances.
- Apogee's lead asset zumilokibart (APG777) targets IL-13 for atopic dermatitis; APG273 targets IL-13/TSLP for asthma.
regulatory
positive
materiality 0.75
June 22, 2026, 7:00 AM ET
Incyte settles CMS dispute over Opzelura Medicaid rebates; records $246M benefit
- CMS will not apply line extension regulation to Opzelura as if it were a line extension of Jakafi; Incyte withdraws lawsuit.
- One-time non-cash benefit of ~$246M in Q2 2026 from reversal of previously accrued liabilities through March 31, 2026.
- No future accruals for potential line extension regulations; expects improvement to Opzelura's gross-to-net.
PRAX
Praxis Precision Medicines, Inc.
regulatory
positive
materiality 0.70
June 22, 2026, 4:43 PM ET
FDA grants Breakthrough Therapy Designation for Praxis Precision Medicines' elsunersen for SCN2A-DEE
- FDA granted Breakthrough Therapy Designation for elsunersen (PRAX-222), an antisense oligonucleotide for seizures in SCN2A Developmental and Epileptic Encephalopathy.
- BTD expedites development and regulatory review; supported by positive topline data from EMBRAVE Part A trial.
- EMBRAVE Part A was a randomized, sham-controlled Phase 1/2 study in nine pediatric patients aged 2–12 years with early-seizure-onset SCN2A-DEE.
CAR
AVIS BUDGET GROUP, INC.
litigation
positive
materiality 0.75
June 22, 2026, 4:30 PM ET
Avis Budget settles Section 16(b) lawsuit for $650M cash with Pentwater
- Settlement of Section 16(b) action with Pentwater Capital Management for $650M in cash.
- Company sued Pentwater for recovery of short-swing profits; settlement resolves that claim.
- Payment subject to court approval; company must demonstrate diligent pursuit and fairness.
PRIM
Primoris Services Corp
earnings
negative
materiality 0.90
June 22, 2026, 4:27 PM ET
Primoris slashes FY2026 guidance, COO exits; Renewables cost overruns persist
- FY2026 net income guidance cut to $71M–$101M from $223M–$234M; EPS now $1.30–$1.85.
- Renewables revenue expected ~$2.1B vs $3.0B in 2025; six projects with cost overruns.
- COO Jeremy Kinch departs effective June 22; CEO Koti Vadlamudi assumes his duties.
AMPG
AmpliTech Group, Inc.
litigation
negative
materiality 0.60
June 22, 2026, 4:15 PM ET
AmpliTech faces shareholder derivative lawsuit over $3.2M crypto phishing loss
- Company was victim of a cyber phishing scam in 2024 resulting in ~$3.2M loss in digital assets.
- Shareholder's law firm sent June 2026 letter indicating intent to file derivative complaint in Nevada.
- Draft complaint alleges directors and officers breached fiduciary duties in connection with the digital currency investment.